comparemela.com

Latest Breaking News On - University of houston college pharmacy - Page 2 : comparemela.com

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.

United-states
Spain
Barcelona
Comunidad-autonoma-de-cataluna
Switzerland
America
Kevin-garey
Eugenie-basseres
Davidp-luci
Company-ph
Society-or-healthcare-epidemiology-of-america
Global-european-society-of-clinical-microbiology

Reduced Vancomycin Susceptibility Tied to Poorer C difficile Outcomes

Poorer outcomes seen for 30-day sustained clinical response and 14-day initial cure rates.

Kevin-garey
Taryna-eubank
University-of-houston
University-of-houston-college-pharmacy
Healthday-news
Clinical-infectious
Houston-college

Vancomycin May Be Losing Strength Against Common Deadly Infection

Key Takeaways

University-of-houston
Texas
United-states
Houston
Americans
Kevin-garey
Anne-gonzales-luna
Us-centers-for-disease
University-of-houston-college-pharmacy
Healthday-news
Houston-college

Vancomycin may be losing effectiveness against C. diff

A new study suggests that the leading antibiotic used to fight Clostridioides difficile, vancomycin, may be losing potency against this killer.

University-of-houston
Texas
United-states
Houston
Americans
Kevin-garey
Anne-gonzales-luna
Us-centers-for-disease
University-of-houston-college-pharmacy
Houston-college
Disease-control

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.

United-states
Spain
Switzerland
Barcelona
Comunidad-autonoma-de-cataluna
America
Kevin-garey
Eugenie-basseres
Davidp-luci
Society-or-healthcare-epidemiology-of-america
Exchange-commission
Research-scientist

vimarsana © 2020. All Rights Reserved.